Crescita, Nuvo Pharma drug delivery, inflammation, neurology news

Nuvo Pharmaceuticals (formerly Nuvo Research Inc.) spun out its drug development business into stand-alone company Crescita. Nuvo Pharmaceuticals will focus on its Pennsaid diclofenac franchise. Crescita is developing topical formulations of drugs for dermatology and pain indications. Its lead pipeline product, Flexicaine, is a topical formulation of lidocaine and tetracaine and is in Phase II testing to treat postherpetic neuralgia. Crescita has rights to develop and market Pliaglis lidocaine/tetracaine in North America from Nuvo Pharmaceuticals. The phase-changing topical formulation of lidocaine and tetracaine is approved in the U.S. and Canada as a topical anesthetic. As of March 1, Crescita had $35 million in cash. ...